The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SUVP.F | +6.35% | -36.03% | -8.54% | +663% |
| S&P | +14.49% | +91.09% | +13.83% | +414% |
Sartorius AG engages in the provision of solutions for biopharmaceutical research. It operates through following divisions: Bioprocess Solutions (BPS), and Lab Products and Service (LPS). The Bioprocess Solutions division focuses on single-use solutions, helps customers manufacture biotech medications and vaccines safely and efficiently. The Lab Products and services division serves the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The company was founded by Florence Sartorius, Sr. in 1870 and is headquartered in Goettingen, Germany.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $985.32M | 13.0% |
| Gross Profit | $459.47M | 21.2% |
| Gross Margin | 46.63% | 3.1% |
| Market Cap | $15.63B | -12.3% |
| Market Cap / Employee | $1.13M | -13.1% |
| Employees | 13.9K | 0.8% |
| Net Income | $72.45M | 193.1% |
| EBITDA | $293.66M | 17.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $458.13M | -29.1% |
| Accounts Receivable | $327.00M | -11.9% |
| Inventory | 972.8 | 0.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.00B | -19.0% |
| Short Term Debt | $1.01B | 820.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 1.34% | 0.5% |
| Return On Invested Capital | 7.73% | -1.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$76.56M | -388.0% |
| Operating Free Cash Flow | $96.65M | -26.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 169.02 | 156.37 | 154.91 | 108.04 | -49.60% |
| Price to Book | 5.10 | 5.92 | 6.11 | 5.01 | -18.50% |
| Price to Sales | 4.21 | 4.31 | 4.64 | 4.13 | -23.41% |
| Price to Tangible Book Value | -4.92 | -6.06 | -6.17 | -5.07 | -15.03% |
| Price to Free Cash Flow TTM | 47.24 | 33.10 | 48.82 | 63.00 | -19.08% |
| Enterprise Value to EBITDA | 68.35 | 73.39 | 73.02 | 74.77 | -25.17% |
| Free Cash Flow Yield | 2.1% | 3.0% | 2.0% | 1.6% | 23.58% |
| Return on Equity | 3.5% | 3.5% | 3.8% | 4.9% | 39.23% |
| Total Debt | $4.72B | $5.00B | $5.46B | $5.02B | -0.67% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
